Biomarker & Intervention Discovery
Long COVID / Post-Acute COVID Sequelae (PACVS)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionSpontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely…
Best-intervention remissionNo approved pharmacotherapy; Paxlovid (nirmatrelvir/ritonavir) — PANORAMIC trial showed no reduction in Long COVID…
Gap sizeVery large — no proven pharmacotherapy; enormous research investment but no approved treatment as of mid-2026
Primary barrierbiological (mechanism not fully understood) + practice (no evidence-based protocol)
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention
Best-intervention remission
No approved pharmacotherapy; Paxlovid (nirmatrelvir/ritonavir) — PANORAMIC trial showed no reduction in Long COVID risk at 6 months if started in acute phase; BC007 (autoantibody neutraliser) — Phase 2 signal; low-dose naltrexone — observational data positive; antihistamine combination (famotidine + cetirizine) — anecdotal
Gap size
Very large — no proven pharmacotherapy; enormous research investment but no approved treatment as of mid-2026
Primary barrier
biological (mechanism not fully understood) + practice (no evidence-based protocol)
Long COVID is a heterogeneous syndrome with multiple proposed mechanisms (viral persistence, autoimmunity, microclotting, dysautonomia, mitochondrial dysfunction); no single treatment works for all patients; fragmented care with poor coordination; many clinicians still do not acknowledge Long COVID as a diagnosis
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Long COVID / Post-Acute COVID Sequelae (PACVS)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."